Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04646005
Title Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals

cervical squamous cell carcinoma


Cemiplimab + ISA101b

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | BEL

No variant requirements are available.